From the perspective of someone who is not a doctor or scientist, from what I have read about eGFR and type 2 diabetes it is more important to track the rate of decline in eGFR as opposed to reading too much into a baseline measurement. To me it will be interesting to see the rates of decline for test vs placebo groups. It would be interesting to know how long patients had been diagnosed diabetics prior to the onset of the trial. I’d be interested to hear what BFW has to say regarding this.